Ontology highlight
ABSTRACT:
SUBMITTER: Oizumi S
PROVIDER: S-EPMC3380886 | biostudies-other | 2012
REPOSITORIES: biostudies-other
Oizumi Satoshi S Kobayashi Kunihiko K Inoue Akira A Maemondo Makoto M Sugawara Shunichi S Yoshizawa Hirohisa H Isobe Hiroshi H Harada Masao M Kinoshita Ichiro I Okinaga Shoji S Kato Terufumi T Harada Toshiyuki T Gemma Akihiko A Saijo Yasuo Y Yokomizo Yuki Y Morita Satoshi S Hagiwara Koichi K Nukiwa Toshihiro T
The oncologist 20120511 6
<h4>Background</h4>For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. This report describes the quality of life (QoL) analysis of that study.<h4>Methods</h4>Chemotherapy-naïve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receiv ...[more]